Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF

Healthcare Biotechnology


GREY:IPHAF - Post by User

Isotechnika Pharma Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by blogon Feb 26, 2011 12:48pm
427 Views
Post# 18199064

More questions

More questions

If Isotechnika receives US approval for voclosporin in Uveitis I would imagine it would be sold off label for psoriasis, irritable bowel, etc. This is also true if we gain psoriasis approval in Canada the drug would be used off label for the other autoimmune indications that are serious.

Can someone in the know confirm this? Doesn’t have to be the same person doing the math for the projected EPS

You guys are the best!!

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities